Add like
Add dislike
Add to saved papers

Progressive Supranuclear Palsy.

Unfortunately, no drug treatment has been shown to benefit patients with progressive supranuclear palsy (PSP) more than modestly or briefly. The multiplicity of neuronal systems and synaptic physiologies that degenerate in this disorder makes a neurotransmitter-specific approach, such as neurotransmitter replacement or reuptake inhibition, unlikely to succeed. Nevertheless, some of these are worth trying in nearly every patient with PSP. Useful drug treatment may ultimately take the form of enhancers of mitochondrial energy metabolism, inducers of endogenous neurotrophic factors, and, even further in the future, inhibitors of tau aggregation or regulators of alternative splicing. The neurologist familiar with PSP can assist patients and their family by providing prognostic information, by avoiding unnecessary diagnostic tests, and by prescribing measures to minimize aspiration and falling, the two most dangerous complications of PSP.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app